P/E ratio for Agile Therapeutics (AGRX)
P/E ratio as of May 2024 (TTM): -0.0101
According to Agile Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -0.0100996. At the end of 2022 the company had a P/E ratio of -0.0444.
P/E ratio history for Agile Therapeutics from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -0.0444 | -92.9% |
| 2021 | -0.6256 | -86.92% |
| 2020 | -4.78 | -25.38% |
| 2019 | -6.41 | 545.48% |
| 2018 | -0.9931 | -66.4% |
| 2017 | -2.96 | -47.62% |
| 2016 | -5.64 | -20.78% |
| 2015 | -7.12 | 30.51% |
| 2014 | -5.46 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Johnson & Johnson JNJ | 11.0 | -108,552.81% | 🇺🇸 USA |
 Pfizer PFE | 15.5 | -154,050.65% | 🇺🇸 USA |
 Merck MRK | 71.8 | -711,472.73% | 🇺🇸 USA |
 TherapeuticsMD TXMD | 0.4407 | -4,464.01% | 🇺🇸 USA |
 Antares Pharma ATRS | 16.4 | -162,890.61% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.